Koudinov Letter to Forbes' Robert Langreth

Attention: Robert Langreth, Forbes, Senior Health Editor

This letter to you is also available at www.alzclub.org

Dear Forbes Editor,

I appreciate Forbes and Forbes series of articles on Alzheimer's and your and your commentators open minded view on the disease.

It's a pity there is no way at Forbes Blog to find a direct contact for articles' authors, as I am particularly interested to contact Robert Langreth of Treatments section, who authored several Blog articles on Alzheimer's clinical trial failure. Please forward this email to Mr. Robert Langreth!

I am Alzheimer's research who is talking on Alzheimer's amyloid beta protein as a normal and essential protein (see PDF of the article Alzheimer's amyloid beta is an essential synaptic protein, not neurotoxic junk for background reading and a preceeding short publication in Science magazine, my other selected reprints can be found here.

I also battle for disclosure of competing ineterests in Alzheimer's. I am a person behind three articles on Alzheimer's in the Wall Street Journal (2004, by Sharon Begley).

For background reading see my "Open letter to President George W. Bush on conduct by scientists, STM journals, and Scientific Institutions" (that should be now re-addressed to a new President of the US, I'll appreciate for your help in making such a letter public, as I am ready to re-address it, hope President Abama has more time on Ethics and Public health issues), and my written evidence to UK Parliamentary Committee on Science publishing "Editorial and Publisher Corruption"

It's a pity that you journalists are like on other Planet, not seeing what scientists like me are talking about for years, while this information is freely available on the Internet. Would you get such a deserved attention and talk on it in time, Eli Lilly would probably not enter just terminated Clinical Trial of a bad thought Alzheimer's drug.


Sincerely,

Alexei Koudinov, MD, PhD, DrSci